Free drug program for Medicare patients with unmet coverage
Recorded opinion date:
The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.
What OIG Said
OIG said giving away a drug can still be low-risk if it’s based on financial need, not referrals or future reimbursement.
✓OIG reviewed a pharma company’s program giving free product to financially eligible Medicare patients who can’t afford their coinsurance or aren’t covered.
✓OIG said this is still “remuneration”, giving something of value, and could trigger Anti-Kickback if the intent were to influence referrals or future coverage.
✓OIG approved it because the decision was based solely on financial need, there were firewalls from marketing, and prescribers could not bill or profit from the free product.
✓Patients can use any provider and change providers at any time; eligibility doesn’t depend on product use history, and no part of the product is billed to Medicare.
OIG WATCH | info@cabraconsulting.com
Diligence Checklist
What you need to be ready to show in diligence
✓Show that eligibility is based on documented financial criteria, not marketing, coverage status, or physician involvement.
✓Prove providers don’t bill for the free drug and can only charge for administration where allowed.
✓Maintain written attestations from both patients and providers, confirming no billing and no reimbursement for the free product.
✓Demonstrate that product shipments are patient-specific, tightly scoped, and controlled, with no resale, reuse, or substitution.
✓Keep a clear separation between patient services and any sales/marketing activities.
If your free drug access model isn’t grounded in financial need and airtight operational controls, you're potentially at risk of scrutiny.
OIG WATCH | info@cabraconsulting.com
Structure not diligence-ready?
Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.
OIG WATCH | info@cabraconsulting.com
Original PDF cover text
FAVORABLE
OIG WATCH
25-01
Free drug program for Medicare patients with unmet coverage
Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.
The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.
What OIG Said
OIG said giving away a drug can still be low-risk if it’s based on financial need, not referrals or future reimbursement.
✓OIG reviewed a pharma company’s program giving free product to financially eligible Medicare patients who can’t afford their coinsurance or aren’t covered.
✓OIG said this is still “remuneration”, giving something of value, and could trigger Anti-Kickback if the intent were to influence referrals or future coverage.
✓OIG approved it because the decision was based solely on financial need, there were firewalls from marketing, and prescribers could not bill or profit from the free product.
✓Patients can use any provider and change providers at any time; eligibility doesn’t depend on product use history, and no part of the product is billed to Medicare.
OIG WATCH | info@cabraconsulting.com
Diligence Checklist
What you need to be ready to show in diligence
✓Show that eligibility is based on documented financial criteria, not marketing, coverage status, or physician involvement.
✓Prove providers don’t bill for the free drug and can only charge for administration where allowed.
✓Maintain written attestations from both patients and providers, confirming no billing and no reimbursement for the free product.
✓Demonstrate that product shipments are patient-specific, tightly scoped, and controlled, with no resale, reuse, or substitution.
✓Keep a clear separation between patient services and any sales/marketing activities.
If your free drug access model isn’t grounded in financial need and airtight operational controls, you're potentially at risk of scrutiny.
OIG WATCH | info@cabraconsulting.com
Structure not diligence-ready?
Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.
OIG WATCH | info@cabraconsulting.com
Original PDF cover text
FAVORABLE
OIG WATCH 25-01
Free drug program for Medicare patients with unmet coverage
Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.